Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1582-4934|22|3|1614-1626

ISSN： 1582-1838

Source： Journal of Cellular and Molecular Medicine, Vol.22, Iss.3, 2018-03, pp. : 1614-1626

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monocytic myeloid‐derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib

By  

Journal of Cellular and Molecular Medicine, Vol. 22, Iss. 2, 2018-02 ,pp. : 1070-1080

John Wiley & Sons Inc

Access to resources Recommend Favorite

The rocky road to personalized medicine in acute myeloid leukaemia

By  

Journal of Cellular and Molecular Medicine, Vol. 22, Iss. 3, 2018-03 ,pp. : 1411-1427

John Wiley & Sons Inc

Access to resources Recommend Favorite

Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling

By  

Journal of Cellular and Molecular Medicine, Vol. 19, Iss. 7, 2015-07 ,pp. : 1742-1755

John Wiley & Sons Inc

Access to resources Recommend Favorite

Striking a new path in reducing cartilage breakdown: combination of antioxidative therapy and chondroanabolic stimulation after blunt cartilage trauma

By  

Journal of Cellular and Molecular Medicine, Vol. 22, Iss. 1, 2018-01 ,pp. : 77-88

John Wiley & Sons Inc

Access to resources Recommend Favorite

Strategy or Spectacle?

By O'Keefe Tricia  

Third Text, Vol. 19, Iss. 6, 2005-11 ,pp. : 617-623

Routledge Ltd

Access to resources Recommend Favorite